Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.43
JAZZ's Cash to Debt is ranked higher than
51% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. JAZZ: 0.43 )
JAZZ' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.43

Equity to Asset 0.40
JAZZ's Equity to Asset is ranked higher than
58% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. JAZZ: 0.40 )
JAZZ' s 10-Year Equity to Asset Range
Min: -0.84   Max: 0.87
Current: 0.4

-0.84
0.87
F-Score: 5
Z-Score: 3.81
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.82
JAZZ's Operating margin (%) is ranked higher than
90% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. JAZZ: 14.82 )
JAZZ' s 10-Year Operating margin (%) Range
Min: -365.84   Max: 46.95
Current: 14.82

-365.84
46.95
Net-margin (%) 2.97
JAZZ's Net-margin (%) is ranked higher than
84% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. JAZZ: 2.97 )
JAZZ' s 10-Year Net-margin (%) Range
Min: -397.15   Max: 49.25
Current: 2.97

-397.15
49.25
ROE (%) 2.50
JAZZ's ROE (%) is ranked higher than
87% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. JAZZ: 2.50 )
JAZZ' s 10-Year ROE (%) Range
Min: 17.9   Max: 111.92
Current: 2.5

17.9
111.92
ROA (%) 1.14
JAZZ's ROA (%) is ranked higher than
87% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. JAZZ: 1.14 )
JAZZ' s 10-Year ROA (%) Range
Min: -113.42   Max: 64.21
Current: 1.14

-113.42
64.21
ROC (Joel Greenblatt) (%) 200.94
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. JAZZ: 200.94 )
JAZZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8082.84   Max: 11377.93
Current: 200.94

-8082.84
11377.93
Revenue Growth (%) 47.60
JAZZ's Revenue Growth (%) is ranked higher than
96% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. JAZZ: 47.60 )
JAZZ' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 47.6
Current: 47.6

0
47.6
EBITDA Growth (%) 59.50
JAZZ's EBITDA Growth (%) is ranked higher than
98% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. JAZZ: 59.50 )
JAZZ' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 75.2
Current: 59.5

0
75.2
EPS Growth (%) 61.70
JAZZ's EPS Growth (%) is ranked higher than
97% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. JAZZ: 61.70 )
JAZZ' s 10-Year EPS Growth (%) Range
Min: -66.4   Max: 76.1
Current: 61.7

-66.4
76.1
» JAZZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

JAZZ Guru Trades in Q4 2013

Steven Cohen 9,178 sh (+242.46%)
John Paulson Sold Out
Chuck Royce 140,600 sh (-6.45%)
Pioneer Investments 241,827 sh (-26.36%)
NWQ Managers 137,154 sh (-29.02%)
RS Investment Management 403,383 sh (-44.79%)
Paul Tudor Jones 2,937 sh (-46.6%)
» More
Q1 2014

JAZZ Guru Trades in Q1 2014

George Soros 3,600 sh (New)
Jim Simons 54,793 sh (New)
Steve Mandel 2,344,486 sh (New)
Joel Greenblatt 7,367 sh (New)
Paul Tudor Jones 4,100 sh (+39.6%)
NWQ Managers 173,919 sh (+26.81%)
Pioneer Investments 268,669 sh (+11.1%)
RS Investment Management 245,052 sh (-39.25%)
Steven Cohen 2,533 sh (-72.4%)
Chuck Royce 31,900 sh (-77.31%)
» More
Q2 2014

JAZZ Guru Trades in Q2 2014

RS Investment Management 323,097 sh (+31.85%)
NWQ Managers 206,924 sh (+18.98%)
Pioneer Investments 311,592 sh (+15.98%)
George Soros Sold Out
Chuck Royce Sold Out
Joel Greenblatt Sold Out
Steve Mandel 2,087,127 sh (-10.98%)
Paul Tudor Jones 1,400 sh (-65.85%)
Jim Simons 11,200 sh (-79.56%)
» More
Q3 2014

JAZZ Guru Trades in Q3 2014

Paul Tudor Jones 1,600 sh (+14.29%)
Jim Simons Sold Out
RS Investment Management 289,982 sh (-10.25%)
Pioneer Investments 276,226 sh (-11.35%)
Steve Mandel 1,788,607 sh (-14.3%)
NWQ Managers 138,705 sh (-32.97%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Steve Mandel 2014-09-30 Reduce -14.3%0.17%$132.55 - $174.37 $ 176.6515%1788607
NWQ Managers 2014-09-30 Reduce -32.97%0.1%$132.55 - $174.37 $ 176.6515%138705
Steve Mandel 2014-06-30 Reduce -10.98%0.15%$124.63 - $154.82 $ 176.6528%2087127
Joel Greenblatt 2014-06-30 Sold Out 0.02%$124.63 - $154.82 $ 176.6528%0
George Soros 2014-06-30 Sold Out $124.63 - $154.82 $ 176.6528%0
Steve Mandel 2014-03-31 New Buy1.4%$125.51 - $174.98 $ 176.6518%2344486
NWQ Managers 2014-03-31 Add 26.81%0.04%$125.51 - $174.98 $ 176.6518%173919
Joel Greenblatt 2014-03-31 New Buy0.02%$125.51 - $174.98 $ 176.6518%7367
George Soros 2014-03-31 New Buy$125.51 - $174.98 $ 176.6518%3600
John Paulson 2013-12-31 Sold Out 0.57%$82.62 - $126.79 $ 176.6571%0
NWQ Managers 2013-12-31 Reduce -29.02%0.05%$82.62 - $126.79 $ 176.6571%137154
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Jazz Pharmaceuticals PLC

Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI
According to GuruFocus Insider Data, the largest insider sells over the past week were: Jazz Pharmaceuticals PLC, Home Depot Inc., Express Scripts and Service Corporation International Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 408.00
JAZZ's P/E(ttm) is ranked higher than
87% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 408.00 )
JAZZ' s 10-Year P/E(ttm) Range
Min: 10.72   Max: 409.79
Current: 408

10.72
409.79
P/B 7.80
JAZZ's P/B is ranked higher than
68% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. JAZZ: 7.80 )
JAZZ' s 10-Year P/B Range
Min: 2.46   Max: 32.21
Current: 7.8

2.46
32.21
P/S 9.81
JAZZ's P/S is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. JAZZ: 9.81 )
JAZZ' s 10-Year P/S Range
Min: 0.22   Max: 12.01
Current: 9.81

0.22
12.01
PFCF 89.60
JAZZ's PFCF is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 89.60 )
JAZZ' s 10-Year PFCF Range
Min: 11.23   Max: 89.98
Current: 89.6

11.23
89.98
EV-to-EBIT 70.44
JAZZ's EV-to-EBIT is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 70.44 )
JAZZ' s 10-Year EV-to-EBIT Range
Min: -8.5   Max: 73.1
Current: 70.44

-8.5
73.1
PEG 5.94
JAZZ's PEG is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 5.94 )
JAZZ' s 10-Year PEG Range
Min: 7.3   Max: 8.56
Current: 5.94

7.3
8.56
Shiller P/E 114.40
JAZZ's Shiller P/E is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 114.40 )
JAZZ' s 10-Year Shiller P/E Range
Min: 97.99   Max: 5846
Current: 114.4

97.99
5846
Current Ratio 3.93
JAZZ's Current Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. JAZZ: 3.93 )
JAZZ' s 10-Year Current Ratio Range
Min: 0.2   Max: 5.1
Current: 3.93

0.2
5.1
Quick Ratio 3.76
JAZZ's Quick Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. JAZZ: 3.76 )
JAZZ' s 10-Year Quick Ratio Range
Min: 0.17   Max: 4.99
Current: 3.76

0.17
4.99

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.90
JAZZ's Price/DCF (Projected) is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 3.90 )
JAZZ' s 10-Year Price/DCF (Projected) Range
Min: 2.23   Max: 6.65
Current: 3.9

2.23
6.65
Price/Median PS Value 2.00
JAZZ's Price/Median PS Value is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. JAZZ: 2.00 )
JAZZ' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 1.82
Current: 2

0.06
1.82
Price/Peter Lynch Fair Value 16.40
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 16.40 )
JAZZ' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.04   Max: 14.94
Current: 16.4

1.04
14.94
Earnings Yield (Greenblatt) 1.40
JAZZ's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. JAZZ: 1.40 )
JAZZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.7
Current: 1.4

1.4
10.7
Forward Rate of Return (Yacktman) 48.72
JAZZ's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. JAZZ: 48.72 )
JAZZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -44.4   Max: 47.3
Current: 48.72

-44.4
47.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:J7Z.Germany
Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its products includes Xyrem, Erwinaze, Prialt. Its commercial activities in the United States are dedicated to its marketed products Xyrem, Erwinaze, Prialt, FazaClo HD, FazaClo LD and Versacloz, as well as providing support for sales of certain of its other products. They have approximately 180 trained, experienced sales professionals who detail its marketed products to physicians in specialties appropriate for each marketed product in the United States. In Europe, they promote Erwinase to hematology and oncology specialists. The Company's commercial activities include marketing and related services and commercial support services. The Company also employ third party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services, to assist with its commercial activities. Some of these competitors include Endo Health Solutions Inc., Forest Laboratories, Inc., Shire Pharmaceuticals, Inc., Teva and Valeant. Other than the manufacturing plant in Italy where they produce some active pharmaceutical ingredients, including the defibrotide drug substance, discussed in more detail below, the company do not have its own manufacturing capability for its products or product candidates, or their active pharmaceutical ingredients, or the capability to package its products. The research, testing, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, recordkeeping, importing and exporting of pharmaceutical products are subject to extensive regulation by the FDA, the European Commission and other regulatory authorities, and regulations differ from country to country. In the United States, the FDA, under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations, regulates the review, approval, manufacturing and marketing of pharmaceutical products.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK